Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Bianca D. Santomasso"'
Autor:
Adam D. Cohen, Samir Parekh, Bianca D. Santomasso, Jaime Gállego Pérez-Larraya, Niels W. C. J. van de Donk, Bertrand Arnulf, Maria-Victoria Mateos, Nikoletta Lendvai, Carolyn C. Jackson, Kevin C. De Braganca, Jordan M. Schecter, Loreta Marquez, Erin Lee, Ingrid Cornax, Enrique Zudaire, Claire Li, Yunsi Olyslager, Deepu Madduri, Helen Varsos, Lida Pacaud, Muhammad Akram, Dong Geng, Andrzej Jakubowiak, Hermann Einsele, Sundar Jagannath
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 2, Pp 1-9 (2022)
Abstract Chimeric antigen receptor (CAR) T-cell therapies are highly effective for multiple myeloma (MM) but their impressive efficacy is associated with treatment-related neurotoxicities in some patients. In CARTITUDE-1, 5% of patients with MM repor
Externí odkaz:
https://doaj.org/article/c52ccfe861b6431796f476020b355a8d
Autor:
Richard J. Lin, Stephanie M. Lobaugh, Martina Pennisi, Hei Ton Chan, Yakup Batlevi, Josel D. Ruiz, Theresa A. Elko, Molly A. Maloy, Connie L. Batlevi, Parastoo B. Dahi, Sergio A. Giralt, Paul A. Hamlin, Elena Mead, Arela Noy, M. Lia Palomba, Bianca D. Santomasso, Craig S. Sauter, Michael Scordo, Gunjan L. Shah, Beatriz Korc-Grodzicki, Soo Jung Kim, Mari Lynne Silverberg, Chelsea A. Brooklyn, Sean M. Devlin, Miguel-Angel Perales
Publikováno v:
Haematologica, Vol 106, Iss 1 (2020)
Externí odkaz:
https://doaj.org/article/fd167d281dcc4ce19c705f931223e5ce
Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan
Publikováno v:
CNS Oncology, Vol 11, Iss 3 (2022)
Antibody–drug conjugates have transformed the treatment of HER2+ breast and other cancers. Unfortunately, the CNS remains a sanctuary site for many such patients in part due to poor macromolecule penetration across the blood–brain tumor barrier.
Externí odkaz:
https://doaj.org/article/9102a2b6b4db49fa8f813117309addab
Autor:
Adam Goldman, Emanuel Raschi, Joab Chapman, Bianca D. Santomasso, Marcelo C. Pasquini, Miguel-Angel Perales, Roni Shouval
Publikováno v:
Blood. 141:673-677
Using 2 global postmarketing surveillance databases, Goldman and colleagues report that progressive multifocal leukoencephalopathy (PML), a viral disease associated with profound immunosuppression, occurs in approximately 0.9 cases per 1000 recipient
Autor:
Geoffrey D.E. Cuvelier, Michelle Schoettler, Nataliya P. Buxbaum, Iago Pinal-Fernandez, Marc Schmalzing, Jörg H.W. Distler, Olaf Penack, Bianca D. Santomasso, Robert Zeiser, Klemens Angstwurm, Kelli P.A. MacDonald, W. Taylor Kimberly, Naomi Taylor, Ervina Bilic, Bernhard Banas, Maike Buettner-Herold, Namita Sinha, Hildegard T. Greinix, Joseph Pidala, Kirk R. Schultz, Kirsten M. Williams, Yoshihiro Inamoto, Corey Cutler, Linda M. Griffith, Stephanie J. Lee, Stefanie Sarantopoulos, Steven Z. Pavletic, Daniel Wolff
Publikováno v:
Transplantation and Cellular Therapy. 28:426-445
Alloreactive and autoimmune responses after allogeneic hematopoietic cell transplantation can occur in nonclassical chronic graft-versus-host disease (chronic GVHD) tissues and organ systems or manifest in atypical ways in classical organs commonly a
Autor:
Renier J. Brentjens, Ola Landgren, Isabelle Riviere, Andreas Rimner, Jonathan Landa, Bianca D. Santomasso, Elena Mead, Aaron D. Goldberg, Mark B. Geyer, Anthony F. Daniyan, Terence J. Purdon, Brigitte Senechal, Xiuyan Wang, Mette Staehr, Sham Mailankody, Eric L. Smith
We present a case of a patient with multiply relapsed, refractory myeloma whose clinical course showed evidence of a synergistic abscopal-like response to chimeric antigen receptor (CAR) T-cell therapy and localized radiotherapy (XRT). Shortly after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1094f1643dcf602c14d770ff9e9259b1
https://doi.org/10.1158/2326-6066.c.6549864
https://doi.org/10.1158/2326-6066.c.6549864
Autor:
Renier J. Brentjens, Ola Landgren, Isabelle Riviere, Andreas Rimner, Jonathan Landa, Bianca D. Santomasso, Elena Mead, Aaron D. Goldberg, Mark B. Geyer, Anthony F. Daniyan, Terence J. Purdon, Brigitte Senechal, Xiuyan Wang, Mette Staehr, Sham Mailankody, Eric L. Smith
Supplementary Data Combined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bda3f6a689e6f1c3ef6e84b0893a324
https://doi.org/10.1158/2326-6066.22542300
https://doi.org/10.1158/2326-6066.22542300
Autor:
Renier J. Brentjens, Michel Sadelain, Hans-Guido Wendel, Mithat Gonen, Yvette Bernal, Daniel Li, Lisa M. DeAngelis, Xi Chen, Behroze Vachha, Hui Liu, Justin R. Cross, Terence Purdon, Brigitte Senechal, Xiuyan Wang, Elizabeth Halton, Elena Mead, Jessica Flynn, Isabelle Riviere, Darin Salloum, Jae H. Park, Bianca D. Santomasso
Table S1: Detailed descriptions of all grade neurotoxicity; Table S2: Correlation between CAR T cell phenotype and neurotoxicity; Table S3: Correlation between CSF cytokines and CSF protein concentrations; Table S4: Definitions of CRS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06c8df8879a42603ffc44dc3d22f8b0e
https://doi.org/10.1158/2159-8290.22532539
https://doi.org/10.1158/2159-8290.22532539
Autor:
Renier J. Brentjens, Michel Sadelain, Hans-Guido Wendel, Mithat Gonen, Yvette Bernal, Daniel Li, Lisa M. DeAngelis, Xi Chen, Behroze Vachha, Hui Liu, Justin R. Cross, Terence Purdon, Brigitte Senechal, Xiuyan Wang, Elizabeth Halton, Elena Mead, Jessica Flynn, Isabelle Riviere, Darin Salloum, Jae H. Park, Bianca D. Santomasso
Figure S1: Detailed time course of neurotoxicity for each patient; Figure S2: Serum cytokines in relation to tocilizumab and corticosteroid administration; Figure S3: Hematopoietic toxicity and coagulopathy in severe neurotoxicity; Figure S4: Angiopo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12631e4215ca5ea039e13bf1341b69c9
https://doi.org/10.1158/2159-8290.22532542.v1
https://doi.org/10.1158/2159-8290.22532542.v1
Publikováno v:
Blood.
With growing indications for Chimeric Antigen Receptor (CAR) T-cell therapy, toxicity profiles are evolving. There is an urgent and unmet need for approaches to optimally manage emerging adverse events that extend beyond the standard paradigm of cyto